Artivion, Inc.'s (NYSE:AORT) Vice President of Human Resources, Matthew A. Getz, has recently sold 5,000 shares of the company's common stock, according to the latest regulatory filings. The transaction, which took place on March 12, 2024, was executed at a weighted average price of $19.9439 per share, with a price range between $19.90 and $20.015 for the shares sold. The total value of the shares disposed of by Getz amounted to approximately $99,719.
The sale has adjusted Getz's direct ownership in the medical device company to 43,536 shares following the transaction. These recent filings provide current and potential investors with up-to-date information on insider transactions at Artivion, Inc., which specializes in surgical and medical instruments and apparatus.
Artivion, formerly known as CryoLife Inc., is incorporated in Delaware and has its business headquarters in Kennesaw, Georgia. The company's stock is publicly traded on the New York Stock Exchange under the ticker symbol AORT.
Investors often monitor insider sales and purchases as they provide insights into the executives' confidence in the company's future prospects. However, it's important to note that there can be various reasons for insiders to sell shares, and such transactions do not necessarily indicate a negative outlook.
For those interested in the detailed figures of the transaction, Getz has offered to provide full information regarding the number of shares sold at each separate price upon request by the Commission staff, the issuer, or a security holder of the issuer.
The transaction was formally reported in compliance with SEC regulations, and the details are accessible to the public for review.
InvestingPro Insights
As Artivion, Inc. (NYSE:AORT) navigates the dynamic landscape of the medical device industry, real-time data and expert analysis become crucial for investors seeking to understand the company's financial health and market position. Here are some key insights from InvestingPro that shed light on Artivion's recent performance and valuation.
Despite the insider sale by Vice President of Human Resources Matthew A. Getz, Artivion's market capitalization stands at a robust 828.63 million USD. The company's revenue has shown a healthy growth over the last twelve months as of Q4 2023, with a 12.82% increase, indicating a positive trend in its business operations. Additionally, Artivion's gross profit margin is impressive at 64.74%, which reflects the company's ability to maintain profitability in its core activities.
Artivion's stock price has experienced significant volatility, as reflected by the InvestingPro Tips, which highlight that the stock price movements are quite volatile and that it is trading near its 52-week high, at 98.05% of the peak value. This could suggest a heightened interest from investors and a potential for price adjustments based on upcoming performance and market conditions.
For investors seeking more comprehensive analysis and additional insights, there are further InvestingPro Tips available. These tips include expectations of net income growth this year and an evaluation of the company's liquidity, where liquid assets exceed short-term obligations. To delve deeper into these metrics and gain access to a full suite of expert tips, consider subscribing to InvestingPro. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With this subscription, investors can access a total of 11 additional InvestingPro Tips to better inform their investment decisions.
Lastly, it's noteworthy that despite the insider sale, analysts predict the company will be profitable this year, which could instill confidence among investors about the company's future prospects. Keeping an eye on the next earnings date on May 2, 2024, will be critical for stakeholders to assess the company's trajectory and performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.